SCHEMBL943620

SCHEMBL943620

c1ccc(CO[C@@H]2CCNC2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 6/20 0.68
SLC6A4 P31645 6/20 0.68
SLC6A3 Q01959 6/20 0.68
KCNH2 Q12809 4/20 0.68
CHRM2 P08172 2/20 0.56
CHRM1 P11229 2/20 0.56
CHRM3 P20309 2/20 0.56
CHRNB2 P17787 1/20 0.56
CHRNA4 P43681 1/20 0.56
HTR2C P28335 2/20 0.54
HTR2B P41595 2/20 0.54
HTR2A P28223 1/20 0.54
HTR7 P34969 1/20 0.54
HTR3A P46098 1/20 0.54
HTR4 Q13639 1/20 0.54
HRH1 P35367 3/20 0.49
HTR1A P08908 1/20 0.46
CTSL P07711 1/20 0.46
CTSB P07858 1/20 0.46
CTSK P43235 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2978516 1.00 SLC6A2 (0.68) SLC6A2SLC6A4SLC6A3KCNH2CHRM2
SCHEMBL110365 1.00 SLC6A2 (0.68) SLC6A2SLC6A4SLC6A3KCNH2CHRM2
Bromide SCHEMBL2177195 0.98 SLC6A2 (0.66) SLC6A2SLC6A4SLC6A3KCNH2CHRM2
Hydrochloric Acid SCHEMBL2175073 0.98 SLC6A2 (0.66) SLC6A2SLC6A4SLC6A3KCNH2CHRM2
Hydrochloric Acid SCHEMBL2520909 0.98 SLC6A2 (0.66) SLC6A2SLC6A4SLC6A3KCNH2CHRM2
Hydrochloric Acid SCHEMBL2173176 0.98 SLC6A2 (0.66) SLC6A2SLC6A4SLC6A3KCNH2CHRM2
Bromide SCHEMBL2177190 0.98 SLC6A2 (0.66) SLC6A2SLC6A4SLC6A3KCNH2CHRM2
Sulfuric Acid SCHEMBL2171810 0.91 SLC6A2 (0.58) SLC6A2SLC6A4SLC6A3KCNH2CHRM2
Sulfuric Acid SCHEMBL2171814 0.91 SLC6A2 (0.58) SLC6A2SLC6A4SLC6A3KCNH2CHRM2
SCHEMBL3161073 0.90 CHRNB2 (0.69) SLC6A2SLC6A4SLC6A3KCNH2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104610122-A Preparation method of trans-2-[(3R)-3-benzyloxy-1-pyrrolidinyl]-1-cyclohexanol UNIV CHINA PHARMA 2015-05-13 CN claimed
WO-2025245046-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2025-11-27 WO disclosed
US-12018029-B2 Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2024-06-25 US disclosed
US-12018029-B2 Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2024-06-25 US disclosed
WO-2022140527-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. (US) 2022-06-30 WO disclosed
US-20210238179-A1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2021-08-05 US disclosed
US-20210238179-A1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2021-08-05 US disclosed
US-20210053972-A1 COMPOUNDS USEFUL AS IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY 2021-02-25 US disclosed
CN-112243440-A Hexahydroxypyrrolo [3,4-c ] pyrrole derivatives useful as LOX inhibitors 癌症研究协会皇家癌症医院 2021-01-19 CN disclosed
EP-3743425-A1 2,8-DIACYL-2,8-DIAZASPIRO[5.5]UNDECANE COMPOUNDS USEFUL AS IMMUNOMODULATORS Bristol-Myers Squibb Company (US) 2020-12-02 EP disclosed
US-20070254945-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2007-11-01 US disclosed
US-20070197632-A1 Aminocyclohexyl ether compounds and uses thereof CARDIOME PHARMA CORP (CA) 2007-08-23 US disclosed
US-20070099983-A1 Aminocyclohexyl ether compounds and uses thereof CARDIOME PHARMA CORP. (CA) 2007-05-03 US disclosed
WO-2007024113-A1 PROCESS FOR THE PREPARATION OF CHIRAL 3-HYDROXY PYRROLIDINE COMPOUND AND DERIVATIVES THEREOF HAVING HIGH OPTICAL PURITY RSTECH CORPORATION (KR) 2007-03-01 WO disclosed
US-20060247300-A1 Aminocyclohexyl ether compounds and uses thereof CARDIOME PHARMA CORP (CA) 2006-11-02 US disclosed
EP-1666459-A2 Aminocyclohexyl ether compounds and uses thereof Cardiome Pharma Corp. (CA) 2006-06-07 EP disclosed
EP-1560812-B1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP (CA) 2006-05-10 EP disclosed
WO-2005097087-A2 MERGED ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2005-10-20 WO disclosed
US-20040049049-A1 Stereoselective synthesis of 1,2-disubstituted cycloalkyls JOHNSON MATTHEY PHARMACEUTICAL MATERIALS, INC. 2004-03-11 US disclosed
WO-2003105756-A2 STEREOSELECTIVE SYNTHESIS OF 1,2-DISUBSTITUTED CYCLOALKYLS JOHNSON MATTHEY PHARMACEUTICAL MATERIALS, INC. (US) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210053972-A1 COMPOUNDS USEFUL AS IMMUNOMODULATORS CD74, HLA-DRB1, CD47 SLC6A2 4227/4885SLC6A4 4457/4885SLC6A3 4462/4885
US-12018029-B2 Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors LOX, LOXL1, LOXL3 SLC6A2 4512/4885SLC6A4 4183/4885SLC6A3 3529/4885
US-20070254945-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF KCNH2, KCNC1, KCNH3 SLC6A2 1012/4885SLC6A4 1837/4885SLC6A3 2179/4885
US-20070197632-A1 Aminocyclohexyl ether compounds and uses thereof KCNH2, KCNC1, KCNH3 SLC6A2 1012/4885SLC6A4 1837/4885SLC6A3 2179/4885
US-20210238179-A1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS LOX, LOXL1, LOXL3 SLC6A2 4512/4885SLC6A4 4183/4885SLC6A3 3529/4885
US-20070099983-A1 Aminocyclohexyl ether compounds and uses thereof KCNH2, KCNC1, KCNH3 SLC6A2 1012/4885SLC6A4 1837/4885SLC6A3 2179/4885
US-20040049049-A1 Stereoselective synthesis of 1,2-disubstituted cycloalkyls CYP8B1, AGTR1, AGTR2 SLC6A2 4010/4885SLC6A4 4235/4885SLC6A3 4090/4885
US-20060247300-A1 Aminocyclohexyl ether compounds and uses thereof KCNH2, KCNC1, KCNH3 SLC6A2 1012/4885SLC6A4 1837/4885SLC6A3 2179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.